Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis.

Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis.

Item
http://www.wikidata.org/entity/Q34636097
Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal CancerEvaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trialKRAS early testing: consensus initiative and cost-effectiveness evaluation for metastatic colorectal patients in an Italian setting.How close are we to standardised extended RAS gene mutation testing? The UK NEQAS evaluation.Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC).Incorporating anti-VEGF pathway therapy as a continuum of care in metastatic colorectal cancer.Current controversies in the management of metastatic colorectal cancer.Chemotherapy Plus Cetuximab versus Chemotherapy Alone for Patients with KRAS Wild Type Unresectable Liver-Confined Metastases Colorectal Cancer: An Updated Meta-Analysis of RCTs.BRAF Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies.Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology.Current treatment options for patients with initially unresectable isolated colorectal liver metastases.Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial.Colorectal liver metastases guidelines, tumor heterogeneity and clonal evolution: can this be translated to patient benefit?FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer.Molecular Biomarkers for the Evaluation of Colorectal Cancer.Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases
P2860

Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis.

Item
http://www.wikidata.org/entity/Q34636097
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Resectability and outcome with ...... d metastases: a meta-analysis.
@ast
Resectability and outcome with ...... d metastases: a meta-analysis.
@en
Resectability and outcome with ...... d metastases: a meta-analysis.
@nl
type
label
Resectability and outcome with ...... d metastases: a meta-analysis.
@ast
Resectability and outcome with ...... d metastases: a meta-analysis.
@en
Resectability and outcome with ...... d metastases: a meta-analysis.
@nl
prefLabel
Resectability and outcome with ...... d metastases: a meta-analysis.
@ast
Resectability and outcome with ...... d metastases: a meta-analysis.
@en
Resectability and outcome with ...... d metastases: a meta-analysis.
@nl
P1433
P1476
P2093
P2888
P304
P31
P356
P433
P478
P577
P6179
P698
P921
P356
P1433
P1476
Resectability and outcome with ...... d metastases: a meta-analysis.
@en
P2093
P2888
P304
P31
P356
P433
P478
P577
P6179
P698
P921